BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

650 related articles for article (PubMed ID: 19938138)

  • 21. Association of cytomegalovirus infection and disease with recurrent hepatitis C after liver transplantation.
    Bosch W; Heckman MG; Pungpapong S; Diehl NN; Shalev JA; Hellinger WC
    Transplantation; 2012 Apr; 93(7):723-8. PubMed ID: 22406819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome.
    Watt KD; Lyden ER; Gulizia JM; McCashland TM
    Liver Transpl; 2006 Jan; 12(1):134-9. PubMed ID: 16382465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcome of living donor liver transplantation for Egyptian patients with hepatitis C (genotype 4)-related cirrhosis.
    Yosry A; Esmat G; El-Serafy M; Omar A; Doss W; Said M; Abdel-Bary A; Hosny A; Marawan I; El-Malt O; Kamel RR; Hatata Y; Ghali A; Sabri H; Kamel S; El-Gbaly H; Tanaka K
    Transplant Proc; 2008 Jun; 40(5):1481-4. PubMed ID: 18589133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation.
    Shiffman ML; Stravitz RT; Contos MJ; Mills AS; Sterling RK; Luketic VA; Sanyal AJ; Cotterell A; Maluf D; Posner MP; Fisher RA
    Liver Transpl; 2004 Oct; 10(10):1248-55. PubMed ID: 15376308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients.
    Berenguer M; Prieto M; San Juan F; Rayón JM; Martinez F; Carrasco D; Moya A; Orbis F; Mir J; Berenguer J
    Hepatology; 2002 Jul; 36(1):202-10. PubMed ID: 12085366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Model for End-Stage Liver Disease score does not predict patient or graft survival in living donor liver transplant recipients.
    Hayashi PH; Forman L; Steinberg T; Bak T; Wachs M; Kugelmas M; Everson GT; Kam I; Trotter JF
    Liver Transpl; 2003 Jul; 9(7):737-40. PubMed ID: 12827562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation.
    de Arias AE; Haworth SE; Belli LS; Burra P; Pinzello G; Vangeli M; Minola E; Guido M; Boccagni P; De Feo TM; Torelli R; Cardillo M; Scalamogna M; Poli F
    Liver Transpl; 2009 Apr; 15(4):390-9. PubMed ID: 19326408
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of hepatitis C histological recurrence rates and patient survival between split and deceased donor liver transplantation.
    Lawal A; Ghobrial R; Te H; Artinian L; Eastwood D; Schiano TD
    Transplant Proc; 2007 Dec; 39(10):3261-5. PubMed ID: 18089367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liver transplantation for HCV-associated liver cirrhosis: predictors of outcomes in a population with significant genotype 3 and 4 distribution.
    Zekry A; Whiting P; Crawford DH; Angus PW; Jeffrey GP; Padbury RT; Gane EJ; McCaughan GW;
    Liver Transpl; 2003 Apr; 9(4):339-47. PubMed ID: 12682883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HCV histological recurrence and survival following liver transplantation in patients with and without hepatocellular carcinoma.
    De Martin E; Senzolo M; Boninsegna S; Guido M; Masier A; Germani G; Tomat S; Brolese A; Neri D; Cillo U; Gambato M; Russo FP; Farinati F; Burra P
    Transplant Proc; 2008; 40(6):1974-5. PubMed ID: 18675104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation.
    Sreekumar R; Gonzalez-Koch A; Maor-Kendler Y; Batts K; Moreno-Luna L; Poterucha J; Burgart L; Wiesner R; Kremers W; Rosen C; Charlton MR
    Hepatology; 2000 Nov; 32(5):1125-30. PubMed ID: 11050065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transforming growth factor β1 polymorphisms and progression of graft fibrosis after liver transplantation for hepatitis C virus--induced liver disease.
    Eurich D; Bahra M; Boas-Knoop S; Lock JF; Golembus J; Neuhaus R; Neuhaus P; Neumann UP
    Liver Transpl; 2011 Mar; 17(3):279-88. PubMed ID: 21384510
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts.
    Khapra AP; Agarwal K; Fiel MI; Kontorinis N; Hossain S; Emre S; Schiano TD
    Liver Transpl; 2006 Oct; 12(10):1496-503. PubMed ID: 16964597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: the updated follow up at 78 months.
    Orlando G; Manzia T; Baiocchi L; Sanchez-Fueyo A; Angelico M; Tisone G
    Transpl Immunol; 2008 Nov; 20(1-2):43-7. PubMed ID: 18773958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative analysis of hepatitis C recurrence and fibrosis progression between deceased-donor and living-donor liver transplantation: 8-year longitudinal follow-up.
    Jain A; Singhal A; Kashyap R; Safadjou S; Ryan CK; Orloff MS
    Transplantation; 2011 Aug; 92(4):453-60. PubMed ID: 21799468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis C.
    Burra P
    Semin Liver Dis; 2009 Feb; 29(1):53-65. PubMed ID: 19235659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A graft to body weight ratio less than 0.8 does not exclude adult-to-adult right-lobe living donor liver transplantation.
    Selzner M; Kashfi A; Cattral MS; Selzner N; Greig PD; Lilly L; McGilvray ID; Therapondos G; Adcock LE; Ghanekar A; Levy GA; Renner EL; Grant DR
    Liver Transpl; 2009 Dec; 15(12):1776-82. PubMed ID: 19938139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma cell hepatitis in hepatitis C virus patients post-liver transplantation: case-control study showing poor outcome and predictive features in the liver explant.
    Ward SC; Schiano TD; Thung SN; Fiel MI
    Liver Transpl; 2009 Dec; 15(12):1826-33. PubMed ID: 19938116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term outcome of hepatitis C infection after liver transplantation.
    Gane EJ; Portmann BC; Naoumov NV; Smith HM; Underhill JA; Donaldson PT; Maertens G; Williams R
    N Engl J Med; 1996 Mar; 334(13):815-20. PubMed ID: 8596547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemical staining of liver grafts with a monoclonal antibody against HCV-Envelope 2 for recurrent hepatitis C after living donor liver transplantation.
    Sadamori H; Yagi T; Iwagaki H; Matsuda H; Shinoura S; Umeda Y; Ohara N; Yanai H; Ogino T; Tanaka N
    J Gastroenterol Hepatol; 2009 Apr; 24(4):574-80. PubMed ID: 19368635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.